Noxopharm Limited
NOX.ASXHealth Care
Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine release syndrome (septic shock).
Market Data
$0.086
-0.0%$26.4M
-100000.0x
$-0.019
0.00%
-0.0%
Latest Earnings
Appendix 4D and FY2026 Half Year Financial Report
27 February 2026
Noxopharm Limited (ASX: NOX) reported a net loss of $1.84M for the half-year ended 31 December 2025, a 49% increase in losses compared to $1.24M in the prior corresponding period. The widening loss was driven by higher finance costs ($500.6K vs $73.6K pcp) and a $451.5K fair value loss on derivative liabilities related to convertible notes, partially offset by a $411.7K gain on modification of convertible notes and $1.73M accrued R&D tax incentive income. The company commenced participant dosing in its HERACLES clinical trial for SOF-SKN™ lupus drug candidate and secured an ATM equity facility of up to $5M post-period, but faces a critical liquidity position with only $91.4K cash on hand at period end. Key points: Commenced participant dosing in the HERACLES Phase 1 clinical trial for SOF-SKN™, its novel lupus drug candidate — a key clinical milestone.; R&D Tax Incentive income of $1.73M accrued for the half-year, with $2.81M received post-period for FY2024-25, materially improving the cash position.; Received a US patent from the USPTO covering Sofra technology's potential use against various cancers, strengthening the IP portfolio.
Recent Announcements
Appendix 4D and FY2026 Half Year Financial Report
Noxopharm Limited (ASX: NOX) reported a net loss of $1.84M for the half-year ended 31 December 2025, a 49% increase in losses compared to $1.24M in the prior corresponding period. The widening loss was driven by higher finance costs ($500.6K vs $73.6K pcp) and a $451.5K fair value loss on derivative liabilities related to convertible notes, partially offset by a $411.7K gain on modification of convertible notes and $1.73M accrued R&D tax incentive income. The company commenced participant dosing in its HERACLES clinical trial for SOF-SKN™ lupus drug candidate and secured an ATM equity facility of up to $5M post-period, but faces a critical liquidity position with only $91.4K cash on hand at period end. Key points: Commenced participant dosing in the HERACLES Phase 1 clinical trial for SOF-SKN™, its novel lupus drug candidate — a key clinical milestone.; R&D Tax Incentive income of $1.73M accrued for the half-year, with $2.81M received post-period for FY2024-25, materially improving the cash position.; Received a US patent from the USPTO covering Sofra technology's potential use against various cancers, strengthening the IP portfolio.
Get real-time alerts for NOX
Receive AI-powered earnings summaries and instant notifications when Noxopharm Limited releases results.
Register Free